Conference Proceedings

EFFECT OF TREATMENT DURATION ON INCIDENCE OF ADVERSE EVENTS (AES) IN A PHASE III STUDY OF CRIZOTINIB VERSUS CHEMOTHERAPY IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Alice T Shaw, Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Keith D Wilner, Paulina Selaru, Anna Polli

JOURNAL OF THORACIC ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013

Citation metrics

1Web of Science

Keywords

Safety
Treatment Duration
Science & Technology
Respiratory System
Life Sciences & Biomedicine
Adverse Events
Crizotinib
Oncology